Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 598 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Complex Patients Clear all

Conditions: Epilepsy
Interventions: Ezogabine: USAN Retigabine (International Nonproprietary Name); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 30
States / cities: Birmingham, Alabama • Huntsville, Alabama • Northport, Alabama + 25 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Trimetrexate glucuronate, Sulfamethoxazole-Trimethoprim, Leucovorin calcium; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1991
U.S. locations: 6
States / cities: San Francisco, California • Chicago, Illinois • New Orleans, Louisiana + 3 more

Conditions: Ventricular Premature Complexes, Blood Pressure
Interventions: PVC Suppression using Flecainide, No PVC Suppression using Placebo; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Sulfamethoxazole-Trimethoprim; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 24
States / cities: San Francisco, California • Stanford, California • Denver, Colorado + 17 more

Conditions: Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Leukemia, Liver Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: ixabepilone; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 2 Years to 21 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Invasive Cryptococcosis
Interventions: ABLC; Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Carney Complex, Chondrosarcoma, Gastrointestinal Stromal Tumor, Paraganglioma
Interventions: Laboratory Biomarker Analysis, Linsitinib, Pharmacological Study; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 8
States / cities: Palo Alto, California • Iowa City, Iowa • Bethesda, Maryland + 4 more

Conditions: Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Marginal Zone Lymphoma, Composite Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Refractory Aggressive B-Cell Non-Hodgkin Lymphoma, Refractory Follicular Lymphoma, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma, Richter Syndrome
Interventions: CD47 Antagonist ALX148, Lenalidomide, Rituximab; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Uterine Neoplasms
Interventions: Carboplatin, Cisplatin, Paclitaxel; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 2
States / cities: Houston, Texas • Seattle, Washington

Conditions: HIV Infections
Interventions: Nystatin; Drug
Lead sponsor: Argus Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Thoracoabdominal Aortic Aneurysm, Thoracoabdominal; Aortic, Aneurysm, Dissecting, Pararenal Aneurysm, Frailty Syndrome
Interventions: Physician Modified Endografts; Device
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2032
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HIV Infections
Interventions: Stavudine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1991
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Hair Diseases, Alopecia, Hair Thinning
Interventions: Scalp tattoo, Canfield HairMetrix®, TargetCool, Microneedle-facilitated lidocaine application; Device
Lead sponsor: Recens Medical, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Diffuse Intrinsic Pontine Glioma, High Grade Glioma, Embryonal Tumor, Ependymal Tumor
Interventions: C7R-GD2.CART cells (IV and ICV infusion); Genetic
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 12 Months to 25 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2041
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections
Interventions: Adefovir, Zidovudine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 9
States / cities: Los Angeles, California • Palo Alto, California • Redwood City, California + 6 more

Conditions: Pancreatic Adenocarcinoma, Adenosquamous Carcinoma, Pancreatic Neuroendocrine Tumor, Pancreatic Neuroendocrine Carcinoma, Gastrointestinal Neuroendocrine Tumor, Gastrointestinal Neuroendocrine Carcinoma, Neuroendocrine Prostate Carcinoma
Interventions: ESK981; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Madison, Wisconsin

Conditions: Complex Partial Seizures
Interventions: vigabatrin; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Uterine Sarcoma, Uterine Leiomyosarcoma, Endometrial Stromal Sarcoma, ESS, Perivascular Epithelioid Cell Tumors, Uterine Adenosarcoma, Uterine PEComa, Estrogen Receptor Positive Tumor, uLMS
Interventions: Elacestrant; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Mycobacterium Avium-intracellular Infection, HIV Infections
Interventions: Clarithromycin; Drug
Lead sponsor: Abbott; Industry
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 1994
U.S. locations: 22
States / cities: Tucson, Arizona • Fresno, California • San Diego, California + 18 more

Conditions: Medically Complex Children, Care Coordination, Case Manager, Care Manager, Collaborative Care, Disease Management, Patient Care Team or Organization, Managed Care, Children With Chronic Conditions, Children With Special Health Care Needs, Shared Care Plan, Patient Care Plan, Health Care and Resource Utilization, Adherence to Care, Functional Status and Productivity, Health Related Quality of Life, Satisfaction With Care, Care Coordinator, Family Experience of Care, Quality Health Care
Interventions: Comprehensive Case Management Service; Behavioral
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 3 Months to 18 Years
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: HIV Infections, Histoplasmosis, Blastomycosis
Interventions: Itraconazole, Amphotericin B; Drug
Lead sponsor: Janssen, LP; Industry
Eligibility: 13 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 9
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Atlanta, Georgia + 4 more

Conditions: AIDS Dementia Complex, HIV Infections
Interventions: Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1992
U.S. locations: 13
States / cities: San Francisco, California • Indianapolis, Indiana • New Orleans, Louisiana + 7 more

Conditions: HIV Infections
Interventions: Interferon alfa-n3; Drug
Lead sponsor: Interferon Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial

Trimetrexate Plus Leucovorin Calcium Rescue Versus Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS

Premature Ventricular Contractions (PVCs) and Blood Pressure Control

A Randomized, Comparative, Prospective Study of Daily Trimethoprim / Sulfamethoxazole (TMS) and Thrice-Weekly TMS for Prophylaxis Against PCP in HIV-Infected Patients

Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy

Safety, Efficacy, and Pharmacokinetics of Amphotericin B Lipid Complex

Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

Malignant Mixed Mesodermal Tumor (MMMT) - Early Stage With Postoperative XRT/Chemotherapy

Pharmacokinetics of Nystatin LF I.V. in Patients With Acquired Immune Deficiency Syndrome-Related Complex (ARC)

Frailty and Physician Modified Fenestrated Endograft for Thoracoabdominal Aortic Pathologies

A Study of Stavudine in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drugs

Efficacy and Safety of TargetCool + Benev Exosomes in Patients With Hair Thinning

C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)

The Safety and Effectiveness of Zidovudine Plus Adefovir in HIV-Infected Patients

Evaluation of the Changes in HIV-1 Burden in Peripheral Blood and Lymphoid Tissue Following Zidovudine ( AZT ) Treatment in HIV-1-Infected Patients With CD4+ Cells Between 100 and 500 Cells/mm3.

Multicenter Trial of ESK981 in Patients With Select Solid Tumors

Sabril for Complex Partial Seizures in Adult Tolerability Study (TS) Patients

Ph 2 Elacestrant in ER Positive Uterine Sarcomas

The Safety and Effectiveness of Clarithromycin in the Prevention of Mycobacterium Avium Complex (MAC) Infection in HIV-Infected Patients

Improving Care for Children With Complex Needs

A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or Histoplasmosis

Comparison of 2',3'-Dideoxyinosine (Didanosine, ddI) and Zidovudine in Therapy of Patients With the AIDS Dementia Complex

Double-Blind, Randomized, Placebo-Controlled Study of Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived) in ARC Patients